457 related articles for article (PubMed ID: 29602570)
21. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
[TBL] [Abstract][Full Text] [Related]
22. Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome.
Silvestri E; Bitossi A; Bettiol A; Emmi G; Urban ML; Mattioli I; Di Scala G; Bacherini D; Lopalco G; Venerito V; Iannone F; Vitale A; Tosi GM; Rizzo S; Fabiani C; Cantarini L; Virgili G; Vannozzi L; Prisco D
Inflammopharmacology; 2020 Jun; 28(3):711-718. PubMed ID: 32157555
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Adalimumab in Patients with Behçet Uveitis: A Systematic Review and Meta-Analysis.
Sener H; Evereklioglu C; Horozoglu F; Gunay Sener AB
Ocul Immunol Inflamm; 2024 Jan; 32(1):89-97. PubMed ID: 36625549
[TBL] [Abstract][Full Text] [Related]
24. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab.
Ucan Gunduz G; Yalcinbayir O; Cekic S; Yildiz M; Kilic SS
J Ocul Pharmacol Ther; 2021 May; 37(4):236-240. PubMed ID: 33512278
[No Abstract] [Full Text] [Related]
25. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C; Vitale A; Emmi G; Lopalco G; Vannozzi L; Guerriero S; Gentileschi S; Bacherini D; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Clin Rheumatol; 2017 Jan; 36(1):191-197. PubMed ID: 27981463
[TBL] [Abstract][Full Text] [Related]
26. Ultra-Widefield Fluorescein Angiography to Monitor Therapeutic Response to Adalimumab in Behcet's Uveitis.
Kim BH; Park UC; Park SW; Yu HG
Ocul Immunol Inflamm; 2022 Aug; 30(6):1347-1353. PubMed ID: 33793368
[TBL] [Abstract][Full Text] [Related]
27. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial.
Suhler EB; Lowder CY; Goldstein DA; Giles T; Lauer AK; Kurz PA; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Tessler HH; Smith JR; Rosenbaum JT
Br J Ophthalmol; 2013 Apr; 97(4):481-6. PubMed ID: 23376607
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease.
Gueudry J; Wechsler B; Terrada C; Gendron G; Cassoux N; Fardeau C; Lehoang P; Piette JC; Bodaghi B
Am J Ophthalmol; 2008 Dec; 146(6):837-44.e1. PubMed ID: 19027420
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.
Bodaghi B; Gendron G; Wechsler B; Terrada C; Cassoux N; Huong du LT; Lemaitre C; Fradeau C; LeHoang P; Piette JC
Br J Ophthalmol; 2007 Mar; 91(3):335-9. PubMed ID: 17050581
[TBL] [Abstract][Full Text] [Related]
30. Clinical experience with adalimumab in the treatment of ocular Behçet disease.
Bawazeer A; Raffa LH; Nizamuddin SH
Ocul Immunol Inflamm; 2010 Jun; 18(3):226-32. PubMed ID: 20482404
[TBL] [Abstract][Full Text] [Related]
31. Anti-TNF-α Therapy for Refractory Uveitis Associated with Behçet's Syndrome and Sarcoidosis: A Single Center Study of 131 Patients.
Kunimi K; Usui Y; Asakage M; Maehara C; Tsubota K; Mitsuhashi R; Umazume A; Kezuka T; Sakai JI; Goto H
Ocul Immunol Inflamm; 2022 Jan; 30(1):223-230. PubMed ID: 32815752
[TBL] [Abstract][Full Text] [Related]
32. Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab.
Al Rashidi S; Al Fawaz A; Kangave D; Abu El-Asrar AM
Ocul Immunol Inflamm; 2013 Dec; 21(6):468-74. PubMed ID: 23734940
[TBL] [Abstract][Full Text] [Related]
33. Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome: A Retrospective Study of Seventy Patients With Vascular Involvement.
Emmi G; Vitale A; Silvestri E; Boddi M; Becatti M; Fiorillo C; Fabiani C; Frediani B; Emmi L; Di Scala G; Goldoni M; Bettiol A; Vaglio A; Cantarini L; Prisco D
Arthritis Rheumatol; 2018 Sep; 70(9):1500-1507. PubMed ID: 29676522
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
[TBL] [Abstract][Full Text] [Related]
35. The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis.
Park SE; Jun JW; Lee DH; Lee SC; Kim M
Yonsei Med J; 2021 Feb; 62(2):177-181. PubMed ID: 33527798
[TBL] [Abstract][Full Text] [Related]
36. The Efficacy of Adalimumab as an Initial Treatment in Patients with Behçet's Retinal Vasculitis.
Yang S; Huang Z; Hu Y; Zhang J; Liu X; Li H; Xie L; Wen F; Liang D; Su W
Front Pharmacol; 2021; 12():609148. PubMed ID: 34239438
[No Abstract] [Full Text] [Related]
37. The Results of Interferon-Alpha Treatment in Behçet Uveitis.
Eser-Ozturk H; Sullu Y
Ocul Immunol Inflamm; 2020 Apr; 28(3):498-504. PubMed ID: 31161949
[No Abstract] [Full Text] [Related]
38. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients.
Fabiani C; Vitale A; Rigante D; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Gentileschi S; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
Clin Rheumatol; 2019 Feb; 38(2):407-415. PubMed ID: 30099655
[TBL] [Abstract][Full Text] [Related]
40. TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS-RELATED MACULAR EDEMA.
Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Sainz de la Maza M; Adán A
Retina; 2018 Jul; 38(7):1361-1370. PubMed ID: 28520640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
